Tuesday, July 25, 2017

Protalix BioTherapeutics (PTX) Completes Private Note Exchange of $9 million Notes Maturing September 2018

**July 26th 2017** 

The #1 BIOTECH Medical Stock to BUY right now

MDCorp. (MDCX)

MDCorp. (MDCX) is a NEW and exciting Biotech Medical stock!

Financially backed by a Billion Dollar Venture Capital Group, MDCorp. (MDCX) has already announced and begun it's plans to acquire or partner with other Biotechs and Medical companies whose cutting edge equipment and pipeline drugs may eliminate the World's deadliest diseases!


It's representative portfolio includes the pipeline drugs of two Biotech stocks trade on the NASDAQ!


Now is the time to buy what has been called "potentially the best medical stock of 2017" while it is still in it's infancy and under the radar!


Do not get left behind, MDCorp. (MDCX) is a MEGA stock in the making!


MDCorp. (MDCX)

The #1 BIOTECH Medical Stock to BUY right now


Backed by a BILLION dollar venture capital group, PMT Advisory, Wall Street's biggest money is behind MDCorp. (MDCX).

With deep roots in the under served Asian marketplace, so much success is already anticipated for MDCX as it extends it's reach from Europe into the Asian and Pacific Rim that it is forecast in the future to see what similar well funded start up stocks experienced with institutional buying from biotech-focused hedge fund Baker Bros. Advisors, along with two big pharmas, Pfizer (PFE) and Johnson and Johnson (JNJ) who all may also try to buy 10% stakes in private offerings!
"Represents the best Biotech ground floor opportunity for investor's so far in 2017, potentially the best medical stock of 2017, Pfizer, Merck and Roche watch out, there is a new sheriff in town!" Stock Market Rater July 2017


MDCorp. (MDCX)

HIGHLIGHTS

-MDCX Amazing share structure of 90M A/S, O/S 88M and a tiny float of 18M (meaning the share price could rise very quickly with limited shares available)



-MDCX Insiders estimated to own a WHOPPING 77% of the O/S, they are not selling! Follow the insiders they know whats coming!

-MDCX FLUSH WITH CASH, backed by Wall Street heavy hitters and BILLION dollar venture capital group, PMT Advisory made up of high net worth individuals in the China/ Hong Kong region including Shawn Mesaros who is the Director of Development at MDCX.

Shawn Mesaros also runs a China-USA private wealth management firm in Seattle PAMRIA providing banking and investment advisory services to high net worth individuals!

PAMRIA is also associated with the MASSIVE Harvest Fund Management, a Chinese asset management company with over $120 BILLION assets under management! Shawn Mesaros is the Managing Director of Portfolio Management, USA and the Mainland China Managing Director of Investment Banking and Private Equity.




-MDCX has announced that it will be acquiring or partnering with Biotechs for specific drugs in their pipeline and also will be acquiring or partnering with medical equipment and medical diagnostic companies.

-MDCX subsidiary Fenix Group International is tasked with leading the research into potential acquisitions and partnerships. Stacked with an amazing talent pool who have worked at America's top Corporations including the US Government Treasury!




-MDCX has identified in it's representative portfolio the initial pipeline drugs it is working on acquiring or partnering up with. Two of the companies trade on the NASDAQ!!

That gives you an indication of the amazing news coming to this EXTREMELY UNDERVALUED biotech, MDCX currently trades under a nickel a share! Crazy cheap cheap, but it will not last, Now is the time to buy shares while this new exciting Biotech Medical company is under the radar!





Portfolio opportunities under Examination 

ITP drug 

ITP may occur when the immune system mistakenly attacks platelets. In children, it may follow a viral infection. In adults, it may be chronic.
Symptoms may include easy bruising, bleeding, and pinpoint-sized reddish-purple spots on the lower legs.
In children, ITP usually resolves without any treatment. Adults commonly need treatment with medications for bleeding. Rarely the spleen may need to be removed.



NASDAQ traded $2.61 per share July 21st 2017






Predictive autoimmune biomarkers Type 1 Diabetes (T1DM)

It can accurately predict the recent treatment failure caused by low insulin secretion, lack of β cell or β cell dysfunction. In addition, by stopping the treatment timely, it can ensure that patients still have insulin secretion. It is with smaller side effects and long-lasting efficacy


A private venture capital backed company headquartered in San Diego




A glucose-responsive insulin for type 1 and type 2 diabetes Type 1 Diabetes (T1DM) and Type 2 Diabetes (T1DM)







NexGen biological drugs to accelerate wound healing 




NASDAQ traded $7.15 per share July 21st 2017




A small molecular weight lipid for diabetic retinopathy 






A private Biotech company dedicated to exploring novel technologies in molecular targets for treatment of diabetes



BUT IT GETS EVEN BETTER





Neuraxon offers Medical Services with over 2000 surgeries in 10 years in 5 countries, specializing in serious brain disorders and diseases.

MDCX in June 2017 announced a letter of intent that they are finalizing a purchase a group of medical distribution companies based in Europe including Neuraxon an awesome UK based company! Revenues from this acquisition are estimated to be $5 MILLION annually and growing!












THERE IS A LOT GOING ON BEHIND THE SCENES, Just look at how busy MDCorp. (MDCX) and it's subsidiary are checking out other potential acquisitions and partnerships





"CONFERENCES + EVENTS WE ATTEND."



-MDCorp. (MDCX) will be uplisting to the OTCQX before uplisting again to the NASDAQ



The company has secured the services of respected law firm, Law Offices of Thomas E. Puzzo, designated OTCQX sponsor

-
MDCorp. (MDCX) has offices in Hong Kong, Australia and China, it also runs operations in
London, Greece, Romania, Bulgaria and Shanghai China


-MDCorp. (MDCX) business flow chart below:


What To Expect Ahead of Synergy Pharmaceuticals Inc (SGYP) 2Q Earnings; Oppenheimer’s Take

**July 26th 2017** 

The #1 BIOTECH Medical Stock to BUY right now

MDCorp. (MDCX)

MDCorp. (MDCX) is a NEW and exciting Biotech Medical stock!

Financially backed by a Billion Dollar Venture Capital Group, MDCorp. (MDCX) has already announced and begun it's plans to acquire or partner with other Biotechs and Medical companies whose cutting edge equipment and pipeline drugs may eliminate the World's deadliest diseases!


It's representative portfolio includes the pipeline drugs of two Biotech stocks trade on the NASDAQ!


Now is the time to buy what has been called "potentially the best medical stock of 2017" while it is still in it's infancy and under the radar!


Do not get left behind, MDCorp. (MDCX) is a MEGA stock in the making!


MDCorp. (MDCX)

The #1 BIOTECH Medical Stock to BUY right now


Backed by a BILLION dollar venture capital group, PMT Advisory, Wall Street's biggest money is behind MDCorp. (MDCX).

With deep roots in the under served Asian marketplace, so much success is already anticipated for MDCX as it extends it's reach from Europe into the Asian and Pacific Rim that it is forecast in the future to see what similar well funded start up stocks experienced with institutional buying from biotech-focused hedge fund Baker Bros. Advisors, along with two big pharmas, Pfizer (PFE) and Johnson and Johnson (JNJ) who all may also try to buy 10% stakes in private offerings!
"Represents the best Biotech ground floor opportunity for investor's so far in 2017, potentially the best medical stock of 2017, Pfizer, Merck and Roche watch out, there is a new sheriff in town!" Stock Market Rater July 2017


MDCorp. (MDCX)

HIGHLIGHTS

-MDCX Amazing share structure of 90M A/S, O/S 88M and a tiny float of 18M (meaning the share price could rise very quickly with limited shares available)



-MDCX Insiders estimated to own a WHOPPING 77% of the O/S, they are not selling! Follow the insiders they know whats coming!

-MDCX FLUSH WITH CASH, backed by Wall Street heavy hitters and BILLION dollar venture capital group, PMT Advisory made up of high net worth individuals in the China/ Hong Kong region including Shawn Mesaros who is the Director of Development at MDCX.

Shawn Mesaros also runs a China-USA private wealth management firm in Seattle PAMRIA providing banking and investment advisory services to high net worth individuals!

PAMRIA is also associated with the MASSIVE Harvest Fund Management, a Chinese asset management company with over $120 BILLION assets under management! Shawn Mesaros is the Managing Director of Portfolio Management, USA and the Mainland China Managing Director of Investment Banking and Private Equity.




-MDCX has announced that it will be acquiring or partnering with Biotechs for specific drugs in their pipeline and also will be acquiring or partnering with medical equipment and medical diagnostic companies.

-MDCX subsidiary Fenix Group International is tasked with leading the research into potential acquisitions and partnerships. Stacked with an amazing talent pool who have worked at America's top Corporations including the US Government Treasury!




-MDCX has identified in it's representative portfolio the initial pipeline drugs it is working on acquiring or partnering up with. Two of the companies trade on the NASDAQ!!

That gives you an indication of the amazing news coming to this EXTREMELY UNDERVALUED biotech, MDCX currently trades under a nickel a share! Crazy cheap cheap, but it will not last, Now is the time to buy shares while this new exciting Biotech Medical company is under the radar!





Portfolio opportunities under Examination 

ITP drug 

ITP may occur when the immune system mistakenly attacks platelets. In children, it may follow a viral infection. In adults, it may be chronic.
Symptoms may include easy bruising, bleeding, and pinpoint-sized reddish-purple spots on the lower legs.
In children, ITP usually resolves without any treatment. Adults commonly need treatment with medications for bleeding. Rarely the spleen may need to be removed.



NASDAQ traded $2.61 per share July 21st 2017






Predictive autoimmune biomarkers Type 1 Diabetes (T1DM)

It can accurately predict the recent treatment failure caused by low insulin secretion, lack of β cell or β cell dysfunction. In addition, by stopping the treatment timely, it can ensure that patients still have insulin secretion. It is with smaller side effects and long-lasting efficacy


A private venture capital backed company headquartered in San Diego




A glucose-responsive insulin for type 1 and type 2 diabetes Type 1 Diabetes (T1DM) and Type 2 Diabetes (T1DM)







NexGen biological drugs to accelerate wound healing 




NASDAQ traded $7.15 per share July 21st 2017




A small molecular weight lipid for diabetic retinopathy 






A private Biotech company dedicated to exploring novel technologies in molecular targets for treatment of diabetes



BUT IT GETS EVEN BETTER





Neuraxon offers Medical Services with over 2000 surgeries in 10 years in 5 countries, specializing in serious brain disorders and diseases.

MDCX in June 2017 announced a letter of intent that they are finalizing a purchase a group of medical distribution companies based in Europe including Neuraxon an awesome UK based company! Revenues from this acquisition are estimated to be $5 MILLION annually and growing!












THERE IS A LOT GOING ON BEHIND THE SCENES, Just look at how busy MDCorp. (MDCX) and it's subsidiary are checking out other potential acquisitions and partnerships





"CONFERENCES + EVENTS WE ATTEND."



-MDCorp. (MDCX) will be uplisting to the OTCQX before uplisting again to the NASDAQ



The company has secured the services of respected law firm, Law Offices of Thomas E. Puzzo, designated OTCQX sponsor

-
MDCorp. (MDCX) has offices in Hong Kong, Australia and China, it also runs operations in
London, Greece, Romania, Bulgaria and Shanghai China


-MDCorp. (MDCX) business flow chart below: